anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ETHNOPHARMACOLOGICAL RELEVANCE: Dachaihu decoction (DCH) is a famous and ancient TCM formula, extensively utilized for over 1800 years in treating gastrointestinal and inflammatory conditions. Our previous study showed that DCH ameliorated intestinal damage and modulated the gut microflora in septic rats. However, the material basis for these effects and the underlying mechanism of action remains ill-defined. We aimed to explore the pharmaceutical ingredients of DCH and its mechanism in mitigating sepsis-induced intestinal epithelial barrier disruption (IEBD).
MATERIALS AND METHODS: Ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS) was used to identify DCH composition. A septic rat model and Caco-2 cells were employed to investigate DCH's effects on IEBD. Transcriptomics and network pharmacology were used to predict potential mechanisms, which were further validated by molecular docking and dynamics simulations. The Modified Murine Sepsis Score (mMSS) and histological assessments were performed. Serum fluorescence intensity of FD4 and the expression of Occludin were evaluated to assess intestinal barrier integrity. And p-PI3K P85, PI3K P85, p-AKT, AKT, Bax and Bcl-2 were determined by Western blot. Cell viability was determined using CCK-8 assay, IL-6 and TNF-α by ELISA and quantitative Real-time PCR (RT-qPCR). The integrity and permeability of single layer of Caco-2 cells were assessed via transepithelial resistance (TEER), alkaline phosphatase (ALP) activity and FD4 permeability.
RESULTS: UHPLC-HRMS identified 180 compounds in DCH. DCH significantly reduced mMSS, improved pathological conditions in the ileum, decreased FD4 serum fluorescence, and enhanced Occludin expression. Transcriptomic and network pharmacology analyses identified the PI3K/AKT pathway as a critical mechanism of action. Molecular docking and dynamics simulations confirmed strong binding of DCH components to PIK3R1. DCH upregulated p-PI3K and p-AKT in ileum tissue of septic rats. DCH improved cell viability, decreased IL-6 and TNF-α, promoted cell survival and Occludin level, and upregulated p-PI3K and p-AKT in LPS-stimulated Caco-2 cells. DCH also maintained TEER, ALP activity and decreased FD4 permeability and these effects were reversed by PI3K inhibitor, LY294002. DCH also downregulated Bax expression and increased Bcl-2 levels in both septic rats and LPS-stimulated Caco-2 cells.
CONCLUSION: DCH ameliorates sepsis-induced IEBD via PI3K/AKT pathway activation, offering a novel therapeutic perspective for sepsis-related intestinal dysfunction.
Oral Genvoya 150/150/200/10 mg \& Epclusa 400/100 mg once daily. Once completed HCV therapy, switch anti-retroviral treatment to Oral Biktarvy 50/200/25 mg.
The invention relates to face-thinning BB cream. The main ingredients in the face-thinning BB cream include a coleus forskohlii root extract, caffeine and escin, which are coated with niosomes. The particle diameter of the niosomes provided by the invention is 200-300nm, and the niosomes are deformable liposomes, have efficient and quick percutaneous absorptivity and super-strong inclusivity, and are a favorable way to mediate percutaneous absorption of functional components. According to the face-thinning BB cream, the coleus forskohlii root extract is used for preventing cellular necrosis and skin ageing; the caffeine can convert triglyceride into free fatty acid to achieve the face-thinning efficacy; and the escin can prevent liquid from leaking into surrounding tissues to avoid facial swelling. The invention further provides a preparation method of the face-thinning BB cream. The main ingredients of the face-thinning BB cream provided by the invention are natural, take synergistic effect to realize the face-thinning efficacy and meanwhile achieve low sensitization. Besides, the BB cream has other functions of common BB cream and thus has a wide market prospect.
The means is used in medicine. It removes any pains and pricking within 30 min. The composition has styptic effect, reinforces and thickens the capillary walls. In case of varicose veins it reduces the weight in the lower limbs and suppresses the inflammatory process. It offers quick regeneration effect in varicose ulcers. The means includes the following components, in wt. %: venom from Vipera ammodytes 0.0001-0.0012, salicylic acid 0.1-2.0, benzocain 0.1-4.0, goose fat from 15.0 to 80.0, propolis 0.1-3.0 and bee wax up to 100. 1 claim
Lipoprotein lipase (LPL) hydrolyzes circulating triglycerides (TGs), releasing fatty acids (FA) and promoting lipid storage in white adipose tissue (WAT). However, the mechanisms regulating adipose LPL and its relationship with the development of hypertriglyceridemia are largely unknown. WAT from obese humans exhibited high PAR2 expression, which was inversely correlated with the LPL gene. Decreased LPL expression was also inversely correlated with elevated plasma TG levels, suggesting that adipose PAR2 might regulate hypertriglyceridemia by downregulating LPL. In mice, aging and high palmitic acid diet (PD) increased PAR2 expression in WAT, which was associated with a high level of macrophage migration inhibitory factor (MIF). MIF downregulated LPL expression and activity in adipocytes by binding with CXCR2/4 receptors and inhibiting Akt phosphorylation. In a MIF overexpression model, high-circulating MIF levels suppressed adipose LPL, and this suppression was associated with increased plasma TGs but not FA. Following PD feeding, adipose LPL expression and activity were significantly reduced, and this reduction was reversed in Par2-/- mice. Recombinant MIF infusion restored high plasma MIF levels in Par2-/- mice, and the levels decreased LPL and attenuated adipocyte lipid storage, leading to hypertriglyceridemia. These data collectively suggest that downregulation of adipose LPL by PAR2/MIF may contribute to the development of hypertriglyceridemia.
PURPOSE:The titled pharmaceutical, containing at least one of L-ascorbic acid, a salt and ester thereof and fat or oil and much active constituents based on the unit weight thereof and scarcely causing separation of the ascorbic acid and fat or oil. CONSTITUTION:An L-ascorbic acid pharmaceutical, obtained by incorporating at least one of L-ascorbic acid, salt, e.g. sodium L-ascorbate, an ester, e.g. L-ascorbic acid stearate, containing <=36% particles having 147-74mum particle size and >=64% particles having <=74mum particle size and fat or oil, e.g. hardened cotton seed oil, hardened corn oil, cocount oil, beef tallow, etc., at 5-65pts.wt. (powdery form):35-95 (liquid form) ratio and, as necessary, adding an emulsifying agent or natural wax thereto to prevent the separation of the above- mentioned both components and having rapid absorption of the active constituents and scarcely oxidizing the fat or oil. The dosage form thereof is preferably a gelatin soft capsule.
The active ingredient in omeprazole delayed-release capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C17H19N3O3S, with a molecular weight of 345.42. The structural formula is:

Omeprazole is a white to off-white crystalline powder that melts with decomposition at about 155°C. It is a weak base, freely soluble in ethanol and methanol, and slightly soluble in acetone and isopropanol and very slightly soluble in water. The stability of omeprazole is a function of pH; it is rapidly degraded in acid media, but has acceptable stability under alkaline conditions.

  
Omeprazole Delayed-Release Capsules meet USP Dissolution Test 2.

  
Omeprazole is supplied as delayed-release capsules for oral administration. Each delayed-release capsule contains either 10 mg, 20 mg or 40 mg of omeprazole in the form of enteric-coated granules with the following inactive ingredients: magnesium hydroxide, mannitol, methacrylic acid copolymer dispersion, povidone and triethyl citrate. The capsule shells have the following inactive ingredients: gelatin, red iron oxide and titanium dioxide. The capsule imprinting ink contains ammonium hydroxide, black iron oxide, ethyl alcohol, isopropyl alcohol, n-butyl alcohol, potassium hydroxide, propylene glycol and shellac.
Patients should be counseledthat antibacterial drugs includingtrimethoprim tablets, USP shouldonly be used to treat bacterialinfections. They do not treat viralinfections (e.g., the common cold).When trimethoprim tablets, USPare prescribed to treat a bacterialinfection, patients should be told thatalthough it is common to feel betterearly in the course of therapy, themedication should be taken exactlyas directed. Skipping doses or notcompleting the full course of therapymay (1) decrease the effectivenessof the immediate treatment and (2)increase the likelihood that bacteriawill develop resistance and will notbe treatable by trimethoprim tablets,USP or other antibacterial drugsin the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with and without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
Disclosed are exemplary drug delivery systems that include controllers, drug delivery devices, and the like. The disclosed drug delivery system and controllers may include a processor, a user interface, a memory, and communication circuitry. An automated drug delivery algorithm is operable to receive a number of different inputs related to a user's glucose and/or ketone levels. The automated drug delivery algorithm(s) of the described drug delivery systems and controllers are operable to adjust to when a user partakes in fasting for a period of time that lasts a day or multiple days. The period of time may be a fasting event, such as a religious holiday or diet regimen. For example, the disclosed automated drug delivery algorithm(s) are operable to receive an indication of initiation of a fasting mode; and modify a drug delivery schedule based on the period of fasting or while in fasting mode.
The invention discloses a traditional Chinese medicine preparation for treating cerebral ischemic stroke. The cerebral ischemic stroke mainly belongs to the categories of apoplexia and the like of the traditional Chinese medical science. The traditional Chinese medicine preparation is made from the following Chinese medicinal herbs: brooklet anemone root, ambergris, wood of largeleaf dogwood, Chinese holly leaves, fruit of thatch screwpine, suffrutescent securinega twig, gloeostereum incarnatum, cone of abies chensiensis van tiegh, radix glycyrrhizae preparata, rhizome of Japanese betony and artemisia capillaris thunb which have effects of nourishing blood, tonifying qi, promoting blood circulation to remove blood stasis, nourishing liver and kidney, relieving dizziness and purging fire. The traditional Chinese medicine preparation is prepared into a decoction. Clinical trials prove that the total effective rate reaches 97.7 percent and is obviously higher than a control group. Therefore, the traditional Chinese medicine preparation is worthy of clinical popularization and application.
BACKGROUND: The burden of neglected tropical diseases (NTDs), HIV/AIDS, tuberculosis, and malaria pose significant public health challenges in Ethiopia. This study aimed to the explore service availability and readiness for NTD care among Ethiopian health facilities treating tuberculosis (TB), HIV/AIDS, and/or malaria.
METHODS: This study utilized secondary data from the Ethiopian Service Provision Assessment 2021-22 survey. The availability of services was calculated as the percentage of HIV/AIDS, tuberculosis, or malaria facilities providing NTD services. Facilities were considered highly prepared to manage any type of NTD if they scored at least half (> 50%) of the tracer items listed in each of the three domains (staff training and guidelines, equipment, and essential medicines). Descriptive statistics and logistic regression models were employed to present the study findings and analyze factors influencing facility readiness, respectively.
RESULTS: Out of 403 health facilities providing NTD care nationally, 179, 183, and 197 also offer TB, HIV/AIDS, and malaria services, respectively. The majority of TB (90.1%), HIV/AIDS (89.6%), and malaria (90.9%) facilities offer soil-transmitted helminth services, followed by trachoma (range 87-90%). The percentages of the aforementioned facilities with at least one trained staff member for any type of NTD were 87.2%, 88.4%, and 82.1%, respectively. The percentage of facilities with guidelines for any type of NTD was relatively low (range 3.7-4.1%). Mebendazole was the most widely available essential medicine, ranging from 69 to 70%. The overall readiness analysis indicated that none of the included facilities (TB = 11.9%; HIV/AIDS = 11.6%; and malaria = 10.6%) were ready to offer NTD care. Specifically, a higher level of readiness was observed only in the domain of medicines across these facilities. Hospitals had better readiness to offer NTD care than did health centers and clinics. Furthermore, a significant associations were observed between facility readiness and factors such as facility type, region, presence of routine management meetings, types of NTD services provided, and fixed costs for services.
CONCLUSIONS: Ethiopian health facilities treating TB, HIV/AIDS, and malaria had an unsatisfactory overall service availability and a lack of readiness to provide NTD care. Given the existing epidemiological risks and high burden of TB, HIV/AIDS, malaria, and NTDs in Ethiopia, there is an urgent need to consider preparing and implementing a collaborative infectious disease care plan to integrate NTD services in these facilities.
Avoid MINOLIRA use during pregnancy.

MINOLIRA, like other tetracycline-class drugs, can cause fetal harm when administered to a pregnant woman. MINOLIRA, like other tetracycline-class drugs, may cause permanent discoloration of the teeth and inhibit bone growth when administered during pregnancy. Based on animal data, tetracyclines cross the placenta, are found in fetal tissues, and can cause skeletal malformation and retardation of skeletal development on the developing fetus. Evidence of embryotoxicity has been noted in animals treated early in pregnancy. If MINOLIRA is used during pregnancy, advise the patient of the potential risk to the fetus and discontinue treatment [see Use in Specific Populations (8.1)].
Participants will meet once a week for 2.5 hours for 8 weeks, plus a 4-hour retreat day, to engage in light stretching exercises and interactive discussions on health topics, such as physical activity, nutrition, sleep, stress, etc. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will ask participants to engage in stretching, read or watch informational content, and answer reflection questions for 30 minutes a day for 5 days a week.
The invention comprises compounds of the formula <FORM:0980883/C2/1> in which R11 is hydrogen, halogen, e.g. Cl, Br, F, trihalomethyl, e.g. CF3, C1- 6 alkyl, C1- 6 alkoxy, nitro or amino, R1 has the values given for R11 and may also be a sulphamoyl group, R0 is a halogen atom or a sulphamoyl group and R is a straight or branched alkoxy or cycloalkoxy group of 1-6 carbon atoms, providing that R1 and R11 are not both hydrogen atoms and one but not both of R1 and R0 are sulphamoyl groups; and their preparation by reacting a 2,4- or 2,5-disulphamoylaniline with a cyclohexanone bearing a substituent R in the 4-position or a reactive functional derivative of such a cyclohexanone such as the ketal, suitably in a solvent such as dimethyl formamide using potassium fluoride or an acid as a catalyst. 4 - R - Substituted cyclohexanones, i.e. 4-methoxy-, 4-ethoxy-, 4-propoxy-, 4-butoxy-, 4-pentyloxy-and 4-isopropoxy-cyclohexanone, are made by hydrogenating the appropriate p-substituted phenol and oxidizing the 4-substituted-cyclohexanol obtained.  Pharmaceutical preparations having saluretic properties comprise the above benzothiadiazone compounds and a diluent or carrier. The preparations may take a form suitable for oral administration such as a tablet, pill or capsule, or may be administered parenterally.
Long-acting dual amylin and calcitonin receptor agonists (DACRAs) are novel candidates for the treatment of type 2 diabetes and obesity due to their beneficial effects on body weight, glucose control, and insulin action. However, how the metabolic benefits are maintained after long-lasting treatment is unknown. This study investigates the long-term anti-obesity and anti-diabetic treatment efficacy of the DACRA KBP-336 alone and combined with the GLP-1 analog semaglutide. Zucker diabetic Sprague Dawley (ZDSD) rats with obesity and diabetes received KBP-336 (4.5 nmol/kg Q3D), semaglutide (50 nmol/kg Q3D), or the combination for 7 mo, and the treatment impact on body weight, food intake, glucose control, and insulin action was evaluated. Furthermore, serum levels of the cardiac fibrosis biomarker endotrophin were evaluated. KBP-336, semaglutide, and the combination lowered body weight significantly compared with the vehicle, with the combination inducing a larger and more sustained weight loss than either monotherapy. All treatments resulted in reduced fasting blood glucose levels and HbA1c levels and improved glucose tolerance compared with vehicle-treated rats. Furthermore, all treatments protected against lost insulin secretory capacity and improved insulin action. Serum levels of endotrophin were significantly lowered by KBP-336 compared with vehicle. This study shows the benefit of combining KBP-336 and semaglutide to obtain significant and sustained weight loss, as well as improved glucose control. Furthermore, KBP-336-driven reductions in circulating endotrophin indicate a clear reduction in the risk of complications. Altogether, KBP-336 is a promising candidate for the treatment of obesity and type 2 diabetes both alone and in combination with GLP-1 analogs.NEW & NOTEWORTHY These studies describe the benefit of combining dual amylin and calcitonin receptor agonists (DACRA) with semaglutide for long-term treatment of obesity and type 2 diabetes. Combination treatment induced sustained weight loss and improved glucose control. A DACRA-driven reduction in a serological biomarker of cardiac fibrosis indicated a reduced risk of complications. These results highlight DACRAs as a promising candidate for combination treatment of obesity and type 2 diabetes and related long-term complications.
Fluoxetine capsules, 10mg and 20 mg. Oral administration, once per day.
Pregnancy Category C

Studies performed in mice, rats, and rabbits have demonstrated no evidence of teratogenic effect due to amoxapine. Embryotoxicity was seen in rats and rabbits given oral doses approximating the human dose. Fetotoxic effects (intrauterine death, stillbirth, decreased birth weight) were seen in animals studied at oral doses 3-10 times the human dose. Decreased postnatal survival (between days 0-4) was demonstrated in the offspring of rats at 5-10 times the human dose. There are no adequate and well-controlled studies in pregnant women. Amoxapine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
E3 ubiquitin ligases play a critical role in plant disease resistance. Among them, the Skp1-Cullin-F-box protein (SCF) ubiquitin ligase complex is the largest family and regulates the ubiquitination of a wide range of proteins. Apple Valsa canker (AVC) is a fungal disease of apple trees caused by the fungus Valsa mali, which can lead to significant economic losses. However, the function of the SCF complex in apple resistance to this disease is still largely unknown. In this study, we identified an SCF ubiquitin ligase complex that can enhance resistance to Valsa canker in apple. Disease evaluation experiments demonstrated that MdSkp1 increased apple resistance to AVC. Furthermore, MdSkp1 interacted with an F-box protein, MdSKIP14, and interacted with a cullin-1 protein, MdCUL1, to form an SCF ubiquitin ligase complex. Additionally, we revealed both MdSKIP14 and MdCUL1 as positive regulators of AVC resistance. In conclusion, our results identified an SCF complex capable of contributing to apple resistance against AVC, providing a theoretical basis for apple disease resistance and the sustainable development of the industry. [Formula: see text] Copyright © 2024 The Author(s). This is an open access article distributed under the CC BY-NC-ND 4.0 International license.
The invention discloses a traditional Chinese medicine preparation for curing scapulohumeral periarthritis and a preparation method thereof. The traditional Chinese medicine preparation is prepared through raw medical materials including turmeric, radix clematidis, radix toddalae, frankincense, myrrh and borneol and comprises turmeric extract, an essential oil component, total saponins extract, a polysaccharide active constituent and a borneol active constituent. Extraction is carried out to the turmeric in an alcohol and water combining method, first the essential oil component is collected, and then the turmeric extract is obtained by refining in a macroporous resin purification method. First the essential oil component is collected from the radix clematidis, the radix toddalae, the frankincense and the myrrh, and then the total saponins extract is obtained by using a macroporous adsorption resin column to purify extracted solution. The polysaccharide active constituent is obtained by adopting a hollow fiber column to carry out ultrafiltration on sediments of the radix clematidis, the radix toddalae, the frankincense and the myrrh. Traditional Chinese medicines and an advanced preparation process are combined, the bioavailability of the obtained preparation is high, and the medicine effect is remarkable.
Postoperative cognitive dysfunction (POCD) is a common complication that affects memory, executive function, and processing speed postoperatively. The pathogenesis of POCD is linked to excessive neuroinflammation and pre-existing Alzheimer's disease (AD) pathology. Previous studies have shown that acupuncture improves cognition in the early phase of POCD. However, POCD can last for longer periods (up to weeks and years). The long-term effects of acupuncture are unknown. In this study, we hypothesized that electroacupuncture (EA) could reduce inflammation and cognitive dysfunction induced by laparotomy over a longer period. We characterized the effects of postoperative EA on cognitive changes and investigated the underlying molecular mechanisms in mice. Laparotomy was performed in 3-month-old mice followed by daily EA treatment for 2 weeks. Our data indicated that laparotomy induced prolonged impairment in memory and executive functions, which were mitigated by postoperative EA. EA also reduced tau phosphorylation and suppressed the activation of tau-related kinases and glia, with effects comparable to ibuprofen. These findings demonstrate the beneficial effects of EA in a mouse model of POCD, suggesting that EA's ability to suppress neuroinflammation may contribute to its protective effects. In conclusion, EA may be a viable non-pharmacological intervention for managing POCD in different phases of the medical condition.